I've been busy in my diabetes work. There's a lot going on there, not least of which is the future of two fairly new but risky diabetes drugs, Avandia (GlaxoSmithKline reports $3 billion in 2006 sales) and Actos (Takeda). An FDA advisory panel is holding a meeting on Avandia today. I'll post about them, and a few other related items, when I can carve out a bit of time ... soon!Monday, July 30, 2007
Time Out
I've been busy in my diabetes work. There's a lot going on there, not least of which is the future of two fairly new but risky diabetes drugs, Avandia (GlaxoSmithKline reports $3 billion in 2006 sales) and Actos (Takeda). An FDA advisory panel is holding a meeting on Avandia today. I'll post about them, and a few other related items, when I can carve out a bit of time ... soon!
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment